{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-sample-retention-and-destruction”
},
“headline”: “SOP for Sample Retention and Destruction”,
“description”: “This SOP defines procedures for the retention and destruction of biological samples collected in clinical trials, in compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements. It includes retention timelines, storage conditions, destruction certification, and regulatory alignment.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 21/12/2025
Standard Operating Procedure for Sample Retention and Destruction
| SOP No. | CR/OPS/086/2025 |
| Supersedes | NA |
| Page No. | 1 of 40 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to define procedures for the retention and destruction of biological samples collected during clinical trials. Proper retention ensures availability of
Scope
This SOP applies to all clinical trial biological samples, including blood, urine, plasma, serum, tissue, genetic material, and pharmacokinetic specimens. It covers retention timelines, long-term storage, destruction certification, vendor qualification, and documentation requirements.
Responsibilities
- Sponsor: Defines retention timelines and destruction policies in protocols and contracts.
- Investigator: Ensures local sample storage complies with regulatory requirements.
- Laboratory Staff: Maintain freezer inventories and destruction logs.
- QA: Audits retention and destruction records for compliance.
- Vendors: Perform secure destruction of biospecimens and provide certificates.
Accountability
The Sponsor is accountable for ensuring retention and destruction practices meet global regulatory standards. The Investigator is accountable for proper handling at site level. QA is accountable for oversight and inspection readiness.
Procedure
1. Retention Timelines
1.1 Retain samples as per protocol or regulatory requirements:
– FDA: 2 years after marketing approval or trial discontinuation.
– EMA: Minimum 25 years for trial-related documents; samples per protocol.
– CDSCO: Minimum 5 years or as defined.
– WHO: 15 years or per sponsor policy.
1.2 Document retention period in Sample Retention Log (Annexure-1).
2. Storage Conditions
2.1 Store samples at validated conditions (−20°C, −80°C, or LN2).
2.2 Maintain Freezer Inventory Log (Annexure-2).
2.3 Monitor temperatures continuously and record daily checks.
3. Sample Release for Testing
3.1 Sponsor authorization required for secondary testing.
3.2 Record sample usage in Retained Sample Utilization Log (Annexure-3).
4. Sample Destruction
4.1 Once retention period expires, samples must be destroyed securely.
4.2 Destruction must follow validated methods (incineration, autoclaving, chemical neutralization).
4.3 Maintain Certificate of Destruction (Annexure-4).
4.4 Witness must be present and sign destruction logs.
5. Subject Withdrawal Requests
5.1 Destroy samples if subject withdraws consent for future use.
5.2 Record action in Withdrawal Sample Log (Annexure-5).
6. Documentation
6.1 All logs must be contemporaneous, legible, and complete.
6.2 Retain destruction certificates permanently in TMF.
Abbreviations
- SOP: Standard Operating Procedure
- QA: Quality Assurance
- TMF: Trial Master File
- FDA: Food and Drug Administration
- EMA: European Medicines Agency
- CDSCO: Central Drugs Standard Control Organization
- WHO: World Health Organization
- LN2: Liquid Nitrogen
Documents
- Sample Retention Log (Annexure-1)
- Freezer Inventory Log (Annexure-2)
- Retained Sample Utilization Log (Annexure-3)
- Certificate of Destruction (Annexure-4)
- Withdrawal Sample Log (Annexure-5)
References
- ICH E6(R2/R3) – Biological Sample Management
- FDA – Retention and Destruction of Samples
- EMA – Sample Retention Guidelines
- CDSCO – Retention Requirements
- WHO – Retention and Destruction of Clinical Samples
Version: 1.0
Approval Section
| Prepared By | Ravi Kumar, Clinical Coordinator |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Principal Investigator |
Annexures
Annexure-1: Sample Retention Log
| Date | Sample ID | Retention Period | Location | Recorded By |
|---|---|---|---|---|
| 01/09/2025 | S-301 | 5 years | Freezer-01 | Meena Sharma |
Annexure-2: Freezer Inventory Log
| Sample ID | Box No. | Position | Date Stored | Stored By |
|---|---|---|---|---|
| S-301 | B-12 | A3 | 01/09/2025 | Lab Tech |
Annexure-3: Retained Sample Utilization Log
| Date | Sample ID | Purpose | Approved By | Remarks |
|---|---|---|---|---|
| 10/09/2025 | S-301 | PK testing | Sponsor | Partial volume used |
Annexure-4: Certificate of Destruction
| Date | Sample IDs | Method | Witness | Vendor |
|---|---|---|---|---|
| 15/09/2030 | S-301 | Incineration | QA Officer | ABC Biowaste Pvt Ltd |
Annexure-5: Withdrawal Sample Log
| Date | Subject ID | Sample ID | Action | Responsible |
|---|---|---|---|---|
| 12/09/2025 | SUBJ-401 | S-305 | Destroyed | Lab Tech |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head Clinical Quality |
For more SOPs visit: Pharma SOP